Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Patent: 5,472,949

« Back to Dashboard

Patent 5,472,949 protects XELODA and is included in one NDA. There has been one Paragraph IV challenge on Xeloda.

Protection for XELODA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 5,472,949

Title: N.sup.4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine compounds, compositions and methods of using same
Abstract:The invention relates to N.sup.4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine derivatives which are useful as an agent for treating tumors, pharmaceutical compositions including the same, a method of treating tumors and a method of preparing N.sup.4 -(substituted-oxycarbonyl)-5'-deoxy-5-fluorocytidine derivatives for treating tumors. Compounds of formula (I), ##STR1## wherein R.sup.1 is a saturated or unsaturated, straight or branched hydrocarbon radical wherein the number of carbon atoms in the longest straight chain of this hydrocarbon radical ranges from three to seven, or is a radical of the formula --(CH.sub.2)n--.sup.Y wherein Y is a cyclohexyl radical, a C.sub.1 -C.sub.4 alkoxy radical or a phenyl radical and wherein when Y is a cyclohexyl radical n is an integer from 0 to 4, and when Y is C.sub.1 -C.sub.4 alkoxy radical or a phenyl radical n is an integer from 2 to 4, and R.sup.2 is a hydrogen atom or a radical easily hydrolyzable under physiological conditions, or a hydrate or solvate thereof. Compounds of formula (I) are useful in the treatment of tumors.
Inventor(s): Arasaki; Motohiro (Kanagawa, JP), Ishitsuka; Hideo (Kanagawa, JP), Kuruma; Isami (Kanagawa, JP), Miwa; Masanori (Kanagawa, JP), Murasaki; Chikako (Kanagawa, JP), Shimma; Nobuo (Kanagawa, JP), Umeda; Isao (Kanagawa, JP)
Assignee: Hoffmann-La Roche Inc. (Nutley, NJ)
Application Number:08/167,392
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;
Patent PDF download available with subscription

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Hoffmann La Roche
XELODA
capecitabine
TABLET;ORAL020896Apr 30, 1998RXNo5,472,949*PED<disabled>Y
Hoffmann La Roche
XELODA
capecitabine
TABLET;ORAL020896Apr 30, 1998RXYes5,472,949*PED<disabled>Y
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,472,949

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
92121538Dec 18, 1992

International Patent Family for Patent: 5,472,949

Country Document Number Publication Date
South Africa9309293Jun 18, 1994
Yugoslavia77993Oct 18, 1996
Yugoslavia49411Jan 16, 2006
El Salvador1993000080Jan 26, 1996
Slovakia144493Oct 05, 1994
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc